drugset / Trial / NCT04647669

World Health Organization (WHO) COVID-19 Solidarity Trial for COVID-19 Treatments

NCT04647669

Phase 3 Unknown 100 enrolled The University of The West Indies
RandomizedParallel-groupOpen-labelTreatment

Summary

In early 2020 there were no approved anti-viral treatments for COVID19 Infection. The SOLIDARITY trial is a multicentre adaptive international randomised trial sponsored by Word Health Organization to determine the efficacy of Remdesivir (daily infusion for 10 days), or Acalabrutinib (orally twice daily for 10 days), or Interferon β1a(daily injection for 6 days) compared with local standard of care in patients admitted to hospital for COVID19 infection on all-cause mortality, stratified by severity of disease at the time of randomisation. The major secondary outcomes are duration of hospital stay and time to first receiving ventilation (or intensive care).

Timeline

Start
2021-06-01
Primary completion
2021-11-30
Completion
2021-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Acalabrutinib Small molecule 100 mg Oral
Comparator Interferon beta-1a Protein / enzyme biologic 10 ug Intravenous
Comparator Interferon beta-1a Protein / enzyme biologic 44 ug Intravenous
Comparator Remdesivir Small molecule 100 mg Intravenous

Indications